Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, tisagenlecleucel is currently the most expensive oncologic therapy. We aimed to determine whether tisagenlecleucel is cost effective compared with currently available treatments. Methods: Markov modeling was used to evaluate tisagenlecleucel in pediatric relapsed or refractory acute lymphoblastic leukemia from a US health payer perspective over a lifetime horizon. The model was informed by recent multicenter, single-arm clinical trials. Tisagenlecleucel (under a range of plausible long-term effectiveness) was compared with blinatumomab, clofarabine combination therapy (clofarabine, etoposide, and cyclophosphamide), and clofarabine monotherapy. Scenario and probabilistic sensitivity analyses were used to explore uncertainty. Main outcomes were life-years, discounted lifetime costs, discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (3% discount rate). Results: With an assumption of a 40% 5-year relapse-free survival rate, tisagenlecleucel increased life expectancies by 12.1 years and cost $61,000/QALY gained. However, at a 20% 5-year relapse-free survival rate, life-expectancies were more modest (3.8 years) and expensive ($151,000/QALY gained). At a 0% 5-year relapse-free survival rate and with use as a bridge to transplant, tisagenlecleucel increased life expectancies by 5.7 years and cost $184,000/QALY gained. Reduction of the price of tisagenlecleucel to $200,000 or $350,000 would allow it to meet a $100,000/QALY or $150,000/QALY willingness-to-pay threshold in all scenarios. Conclusion: The long-term effectiveness of tisagenlecleucel is a critical but uncertain determinant of its cost effectiveness. At its current price, tisagenlecleucel represents reasonable value if it can keep a substantial fraction of patients in remission without transplantation; however, if all patients ultimately require a transplantation to remain in remission, it will not be cost effective at generally accepted thresholds. Price reductions would favorably influence cost effectiveness even if long-term clinical outcomes are modest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 3×
“Cost of follow-up care (75%-150%) Cost of treatment admin (75%-150%) Cost of pharmaceuticals (75%-150%) Cost of adverse events (75%-150%) Cost of HSCT ($400,000-$700,000) Cost of grade 4 CRS ($38,000-$250,000) Cost of treatment admin, adverse event, and follow-up care (75%-150%) Cost of care after cure (50%-500%) Stan…”
BackgroundSelf-citationSanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Self-citationRecommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026 · cited 3×
“Cost of follow-up care (75%-150%) Cost of treatment admin (75%-150%) Cost of pharmaceuticals (75%-150%) Cost of adverse events (75%-150%) Cost of HSCT ($400,000-$700,000) Cost of grade 4 CRS ($38,000-$250,000) Cost of treatment admin, adverse event, and follow-up care (75%-150%) Cost of care after cure (50%-500%) Stan…”
Background
Cited by
Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177
Awasthi, R., Maier, H. J., Zhang, J., & Lim, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2210046 · Cited by 123
Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.
Badar, T., & Shah, N. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0706-6 · Cited by 27
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
“In addition, the high-cost and labor-intensive manufacturing processes further restricts the wider application of ACT (146,147).”
Metadata
- Authors
- Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q. L., Davis, K. L., Owens, D. K., & Goldhaber-Fiebert, J. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-11-10
- Volume
- 36
- Issue
- 32
- Pages
- 3192-3202
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2890955229
- Cited by
- 143
- References
- 5
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2018.79.0642
- The paper
- Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q. L., Davis, K. L., Owens, D. K., & Goldhaber-Fiebert, J. D. (2018). Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.79.0642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.